Discussing Mindset Pharma’s 2022 Milestones and Future Plans with James Lanthier
Mindset's recent accomplishments have set the stage for its psychedelic drug candidates to be first in human clinical trials by 2023.
Similar Posts
Senator Scott Wiener Discusses Senate Bill 519
In this Psychedelic Spotlight exclusive, we speak with California Senator,…
The Great Microdosing Debate
Microdosing psychedelics is more popular than ever, but is there any evidence that it works? We unpack the great microdosing debate.
Are We Being Exposed to Psychedelics More Than Ever Before? Survey Says…It’s Complicated
A study of American newspaper mentions of psychedelics doesn’t stack up to what leaders in the industry are observing in the media landscape at large.
Hawaii Moves to Legalize Psilocybin Treatment
Hawaii may soon legalize psilocybin therapy for the treatment of a range of mental health issues, according to proposed legislation.
How Long Until Psychedelic Stocks Payoff?
Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing in psychedelic stocks.
Shrooms vs. LSD: Differences, Similarities & Research Progress
A direct comparison between the subjective effects, onset time, mystical experience and research of shrooms vs. LSD.